Given the role of PDE7 in cAMP degradation and its regulatory interaction with PKA, targeting PDE7 may increase the cAMP-PKA signaling, enhancing the paclitaxel-induced apoptosis via mitochondrial dysfunction and suppression of survival pathways, thus improving the effectiveness in ovarian cancer. This evidence concerns the gene PDE7A and ovarian carcinoma.